Complementary and alternative medicines in cancer patients

被引：15

作者：

Bosacki, Claire ^{[1
]}

Vallard, Alexis ^{[1
]}

Gras, Mathilde ^{[2
]}

Daguenet, Elisabeth ^{[2
]}

Morisson, Stephanie ^{[3
]}

Mery, Benoite ^{[4
]}

Jmour, Omar ^{[1
]}

Guy, Jean-Baptiste ^{[1
]}

Magne, Nicolas ^{[1
]}

机构：

[1] Inst Cancerol Lucien Neuwirth, Dept Radiotherapie, 108 Bis,Ave Albert Raimond,BP 60008, F-42271 St Priest En Jarez, France

[2] Inst Cancerol Lucien Neuwirth, Dept Univ Rech & Educ, 108 Bis,Ave Albert Raimond,BP 60008, F-42271 St Priest En Jarez, France

[3] Inst Cancerol Lucien Neuwirth, Dept Interdisciplinaire Soins Support Patient Onc, 108 Bis,Ave Albert Raimond,BP 60008, F-42271 St Priest En Jarez, France

[4] Inst Cancerol Lucien Neuwirth, Dept Oncol Med, 108 Bis,Ave Albert Raimond,BP 60008, F-42271 St Priest En Jarez, France

来源：

BULLETIN DU CANCER | 2019年 / 106卷 / 05期

关键词：

Complementary and alternative medicines; Unconventional care practices; Cancer; Level of evidence; Literature review; Supportive care; Assessment of practices; QUALITY-OF-LIFE; BREAST-CANCER; HYPNOSIS INTERVENTION; HOMEOPATHY; PAIN; SYMPTOMS; THERAPY; TRIAL; CHEMOTHERAPY; METAANALYSIS;

D O I：

10.1016/j.bulcan.2019.02.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Complementary and alternative medicines (CAMs) play more and more a significant role both in France and all over the world. Yet, their definition and their role in cancer treatments legitimately raise concerns. This article aims at establishing a picture of the CAMs admitted by the French Medical Board as well as those which are new or in common medical practices in France. We start with a brief reminder of their origin, their status and how they are used. Then, we review the literature about some of the best clinical trials using CAMs in cancer patients. To finish, we try to understand what makes CAMs so thrilling, but also why they create controversy and which common points they may have with conventional medicine.

引用

页码：479 / 491

页数：13

共 50 条

[1] Complementary and alternative medicines taken by cancer patients
Simon, L.
Prebay, D.
Beretz, A.
Bagot, J-L
Lobstein, A.
Rubinstein, I.
Schraub, S.
[J]. BULLETIN DU CANCER, 2007, 94 (05) : 483 - 488
[2] Potential health risks of complementary alternative medicines in cancer patients
Werneke, U
Earl, J
Seydel, C
Horn, O
Crichton, P
Fannon, D
[J]. BRITISH JOURNAL OF CANCER, 2004, 90 (02) : 408 - 413
[3] Assessing health risks of complementary alternative medicines in cancer patients
Shia, G
Shaw, D
Dargan, PI
[J]. BRITISH JOURNAL OF CANCER, 2004, 91 (05) : 995 - 996
[4] Potential health risks of complementary alternative medicines in cancer patients
U Werneke
J Earl
C Seydel
O Horn
P Crichton
D Fannon
[J]. British Journal of Cancer, 2004, 90 : 408 - 413
[5] Assessing health risks of complementary alternative medicines in cancer patients
G Shia
D Shaw
P I Dargan
[J]. British Journal of Cancer, 2004, 91 : 995 - 996
[6] Patients use complementary and alternative medicines
Kerr, C
[J]. LANCET ONCOLOGY, 2005, 6 (11): : 832 - 832
[7] Patients use complementary and alternative medicines
Kerr, C
[J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (18) : 2781 - 2781
[8] The use of complementary alternative medicines in advanced cancer patients followed at home
Mercadante, Sebastiano
Bellavia, Giuseppe
Lo Cascio, Alessio
Dabbene, Marcella
di Silvestre, Grazia
Casuccio, Alessandra
[J]. SUPPORTIVE CARE IN CANCER, 2022, 30 (03) : 2003 - 2008
[9] Reply: Assessing health risks of complementary alternative medicines in cancer patients
U Werneke
J Earl
C Seydel
O Horn
P Crichton
D Fannon
[J]. British Journal of Cancer, 2004, 91 : 996 - 997
[10] Reply: Assessing health risks of complementary alternative medicines in cancer patients
Werneke, U
Earl, J
Seydel, C
Horn, O
Crichton, P
Fannon, F
[J]. BRITISH JOURNAL OF CANCER, 2004, 91 (05) : 996 - 997

← 1 2 3 4 5 →